MX2020008902A - Analogos de compstatina y sus usos medicos. - Google Patents
Analogos de compstatina y sus usos medicos.Info
- Publication number
- MX2020008902A MX2020008902A MX2020008902A MX2020008902A MX2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A
- Authority
- MX
- Mexico
- Prior art keywords
- compstatin
- analogues
- introduction
- complement
- inhibiting activity
- Prior art date
Links
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 title abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 108010027437 compstatin Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen análogos de compstatina que tienen unión y actividad de inhibición del complemento mejoradas en comparación con el péptido de compstatina de 13 aminoácidos (ICVVQDWGHHRCT (C2-C12 cíclico)), en particular análogos de compstatina que adicionalmente poseen propiedades fisicoquímicas útiles, tales como aumento de solubilidad. Estos análogos incluyen variantes con un residuo de isoleucina en la posición 3 en lugar del residuo de valina de tipo natural, que proporciona péptidos de compstatina con unión y actividad de inhibición del complemento mejoradas y también permite la introducción de otras modificaciones, por ejemplo, modificaciones que son capaces de aumentar la solubilidad, tal como la introducción de aminoácidos cargados o polares en la posición 9 y/o la introducción de secuencias de N- y/o C-terminales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18158834 | 2018-02-27 | ||
| EP18214949 | 2018-12-20 | ||
| PCT/EP2019/054685 WO2019166411A1 (en) | 2018-02-27 | 2019-02-26 | Compstatin analogues and their medical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008902A true MX2020008902A (es) | 2020-12-03 |
Family
ID=65516661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008902A MX2020008902A (es) | 2018-02-27 | 2019-02-26 | Analogos de compstatina y sus usos medicos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11965039B2 (es) |
| EP (1) | EP3759120A1 (es) |
| JP (1) | JP7690287B2 (es) |
| KR (1) | KR20200135797A (es) |
| CN (1) | CN112041330B (es) |
| AU (1) | AU2019228639A1 (es) |
| BR (1) | BR112020017385A2 (es) |
| CA (1) | CA3091993A1 (es) |
| CL (1) | CL2020002197A1 (es) |
| CO (1) | CO2020011027A2 (es) |
| IL (1) | IL276877A (es) |
| MX (1) | MX2020008902A (es) |
| PE (1) | PE20201254A1 (es) |
| RU (1) | RU2020128624A (es) |
| SG (1) | SG11202008177WA (es) |
| TW (1) | TW202000686A (es) |
| WO (1) | WO2019166411A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017385A2 (pt) | 2018-02-27 | 2020-12-15 | Zp Spv 3 K/S | Análogos de compstatina, métodos e seus usos médicos |
| HUE057693T2 (hu) | 2018-04-06 | 2022-05-28 | Univ Pennsylvania | Fokozott oldhatóságú és javított farmakokinetikai tulajdonságú kompsztatin analógok |
| ES3049784T3 (en) * | 2019-08-27 | 2025-12-18 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| WO2021231676A1 (en) * | 2020-05-15 | 2021-11-18 | Eli Lilly And Company | Extended time action acylated insulin compounds |
| JP2023538807A (ja) * | 2020-07-16 | 2023-09-12 | セッドぺー エスぺーヴェー ３ カー／エス | 補体因子ｃ３の阻害剤及びそれらの医学的使用 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| EP4622992A1 (en) * | 2022-11-24 | 2025-10-01 | Amyndas Pharmaceuticals US LLC | Compstatin analogs for vector-based therapy |
| CN119219741A (zh) * | 2023-06-29 | 2024-12-31 | 刘晓蓉 | 新型补体抑制剂及其制备、应用和产品 |
| US20260234189A1 (en) | 2025-01-24 | 2026-08-13 | Boehringer Ingelheim International Gmbh | Novel and stable compstatin analogues |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000505068A (ja) | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1999013899A1 (en) * | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| US7989589B2 (en) | 2002-09-20 | 2011-08-02 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved activity |
| CN101325963B (zh) | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
| ES2390828T3 (es) | 2005-11-28 | 2012-11-16 | The Trustees Of The University Of Pennsylvania | Análogos potentes de la compstatina |
| WO2008153963A1 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-c3 complex and use for rational drug design |
| WO2010039690A1 (en) | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| CA2760839C (en) | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| PL2753636T3 (pl) * | 2011-09-07 | 2020-05-18 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych |
| EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2013142362A1 (en) | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
| WO2014078734A2 (en) * | 2012-11-15 | 2014-05-22 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| WO2014100407A1 (en) | 2012-12-19 | 2014-06-26 | The Regents Of The University Of California | Compstatin analogs |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US10213476B2 (en) | 2014-03-17 | 2019-02-26 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved potency and pharmacokinetic properties |
| WO2016049385A1 (en) | 2014-09-24 | 2016-03-31 | Apellis Pharmaceuticals, Inc. | Methods and compositions for cancer treatment and treatment selection |
| US20180057538A1 (en) | 2016-08-26 | 2018-03-01 | The Regents Of The University Of California | Potent and highly soluble pegylated compstatin peptides |
| BR112020017385A2 (pt) * | 2018-02-27 | 2020-12-15 | Zp Spv 3 K/S | Análogos de compstatina, métodos e seus usos médicos |
| ES3049784T3 (en) * | 2019-08-27 | 2025-12-18 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| JP2023538807A (ja) | 2020-07-16 | 2023-09-12 | セッドぺー エスぺーヴェー ３ カー／エス | 補体因子ｃ３の阻害剤及びそれらの医学的使用 |
-
2019
- 2019-02-26 BR BR112020017385-1A patent/BR112020017385A2/pt not_active Application Discontinuation
- 2019-02-26 EP EP19706665.7A patent/EP3759120A1/en active Pending
- 2019-02-26 US US16/976,439 patent/US11965039B2/en active Active
- 2019-02-26 KR KR1020207027897A patent/KR20200135797A/ko not_active Withdrawn
- 2019-02-26 WO PCT/EP2019/054685 patent/WO2019166411A1/en not_active Ceased
- 2019-02-26 CN CN201980015920.1A patent/CN112041330B/zh active Active
- 2019-02-26 CA CA3091993A patent/CA3091993A1/en active Pending
- 2019-02-26 SG SG11202008177WA patent/SG11202008177WA/en unknown
- 2019-02-26 RU RU2020128624A patent/RU2020128624A/ru unknown
- 2019-02-26 MX MX2020008902A patent/MX2020008902A/es unknown
- 2019-02-26 AU AU2019228639A patent/AU2019228639A1/en not_active Abandoned
- 2019-02-26 JP JP2020545488A patent/JP7690287B2/ja active Active
- 2019-02-26 PE PE2020001288A patent/PE20201254A1/es unknown
- 2019-02-27 TW TW108106905A patent/TW202000686A/zh unknown
-
2020
- 2020-08-23 IL IL276877A patent/IL276877A/en unknown
- 2020-08-26 CL CL2020002197A patent/CL2020002197A1/es unknown
- 2020-09-03 CO CONC2020/0011027A patent/CO2020011027A2/es unknown
-
2024
- 2024-03-11 US US18/601,031 patent/US12600749B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202000686A (zh) | 2020-01-01 |
| KR20200135797A (ko) | 2020-12-03 |
| RU2020128624A (ru) | 2022-03-28 |
| AU2019228639A1 (en) | 2020-09-17 |
| US20240309046A1 (en) | 2024-09-19 |
| CL2020002197A1 (es) | 2021-03-05 |
| US20230192770A1 (en) | 2023-06-22 |
| US12600749B2 (en) | 2026-04-14 |
| WO2019166411A1 (en) | 2019-09-06 |
| PE20201254A1 (es) | 2020-11-16 |
| SG11202008177WA (en) | 2020-09-29 |
| EP3759120A1 (en) | 2021-01-06 |
| IL276877A (en) | 2020-10-29 |
| US11965039B2 (en) | 2024-04-23 |
| BR112020017385A2 (pt) | 2020-12-15 |
| CN112041330A (zh) | 2020-12-04 |
| JP7690287B2 (ja) | 2025-06-10 |
| CN112041330B (zh) | 2024-12-27 |
| JP2021515759A (ja) | 2021-06-24 |
| CA3091993A1 (en) | 2019-09-06 |
| CO2020011027A2 (es) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002433A (es) | Análogos de compstatina y sus usos médicos. | |
| CO2020011027A2 (es) | Análogos de compstatina y sus usos médicos | |
| MX2023000679A (es) | Inhibidores del factor c3 del complemento y sus usos medicos. | |
| EP2476699A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| BR112022012057A2 (pt) | Novos métodos de entrega celular | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| MX2025001402A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas | |
| WO2006090810A3 (en) | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides | |
| MX2021001507A (es) | Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. | |
| WO2016210370A3 (en) | Synthetic peptide compounds and methods of use | |
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| MX2010005816A (es) | Epítopos de péptido de stat3. | |
| ATE551353T1 (de) | Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten | |
| WO2015110809A3 (en) | Drug delivery system | |
| BR112022005782A2 (pt) | Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante | |
| EP4403566A3 (en) | Peptides with vasodilatory and/or diuretic functions | |
| MX2018012716A (es) | Peptidos bioactivos pegilados y usos de los mismos. | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. |